according to the 2021 annual report released on April 19, Chongqing Pharscin Pharmaceutical Co.Ltd(002907) 4, the company achieved an operating revenue of 846 million yuan last year, a year-on-year decrease of 4.12%; The net profit attributable to the parent company was 917804 million yuan, a year-on-year decrease of 22.99%; The net profit after deducting non profit was 805759 million yuan, a year-on-year decrease of 9.56% and earnings per share of 0.23 yuan. The company’s profit distribution plan for the year of 21 is RMB 0.50 (including tax) for 10 dividends.
The company explained that the decline in the main business income during the reporting period was mainly due to the decline in the sales revenue of cooperative products orlistat capsules and the stagnant sales of chemical drugs; If this factor is excluded, the company’s operating revenue in 2021 increased by 9.87% year-on-year, of which the sales revenue of exclusive Chinese patent medicine varieties increased by 19.72% year-on-year. The main reason for the decline in profits was that the company continued to accelerate innovation and upgrading, and the R & D investment in innovative drugs, generic drugs and large health varieties increased significantly. During the reporting period, the R & D investment of the company increased by 79.71% year-on-year and the R & D expenses increased by 14.38%. In addition, the decrease of government subsidies related to income and the increase of sales expenses and depreciation expenses also constitute the profit reduction factors.
The company said that with the gradual implementation of the new business cooperation plan of orlistat capsule and the continuous introduction of a number of new products to the market, the growth of the company’s revenue scale is expected to obtain new strong support. In the future, the company will launch 2-3 new products every year, and the steady growth of the exclusive Chinese patent medicine sector will gradually offset the adverse factors affecting the revenue and profit at this stage, and the continuous investment in R & D will win 5-10 years of development opportunities for the company.
It is worth noting that last year, the company officially entered the special medical food track and is promoting the development of relevant special medical food in the field of weight loss and nutritional treatment of pancreatitis. According to relevant research data, the market scale of China’s special medical food industry is growing rapidly. It is expected to exceed 10 billion yuan in 2021, with broad development prospects. At present, the company has created two special medical food products to be developed, namely “shukangyoujia liquid diet short peptide version” and “shukangyoujia liquid diet crystal version”, and is actively building a special medical food production line and cultivating a team with the R & D, analysis, registration and production capacity of special medical food. It is expected that by June this year, the special medical food production line will be officially completed and is expected to become the first special medical food production line in Sichuan and Chongqing.
Since the beginning of this year, the company has sold the special food formula introduced from its partners nationwide as nutritious food through its independent commercialization ability, and laid out a big health track in the field of digestion and weight loss through the sales of nutritious food, which has a positive impact on supplementing the company’s operating income and cash flow in the short term. Next, the company will actively tiktok the market, and build up the new media matrix of jitter, know, Xiao Hong, B station, etc., to help the product to promote the quantity of products through multiple channels.
Looking forward to 2022, Chongqing Pharscin Pharmaceutical Co.Ltd(002907) said that it would continue to fully support the promotion of innovative drug pipeline under research and achieve the predetermined goal, continue to build innovative drug technology platform and expand talent echelon; At the same time, we will do a good job in the sales and promotion of intensively purchased varieties, new medical insurance varieties, newly introduced varieties, five exclusive Chinese patent medicines and special medical food, strengthen production quality management, promote cost reduction and efficiency increase, and improve the company’s product power, marketing power, R & D power and core competitiveness as a whole.
